Want to see TNXP full AI Analyst Report?
TNXP Stock Chart & Stats
$15.08
-$0.02(-7.15%)
At close: 4:00 PM EST
$15.08
-$0.02(-7.15%)
Day’s Range― - ―
52-Week Range$10.03 - $69.97
Previous CloseN/A
Volume36.66M
Average Volume (3M)561.51K
Market Cap
$175.03M
Enterprise Value$4.29
Total Cash (Recent Filing)$185.47M
Total Debt (Recent Filing)$1.29M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Aug 10, 2026EPS Estimate
-2.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.66
Shares Outstanding15,940,801
10 Day Avg. Volume551,436
30 Day Avg. Volume561,511
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.54
Price to Sales (P/S)10.14
P/FCF Ratio-1.29
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$37.67Price Target Upside149.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-10.27
Revenue Forecast (FY)$34.22M
Bulls Say, Bears Say
Bulls Say
Reimbursement ExpansionSubstantive, expanding payer coverage materially increases the addressable patient population and durable access to TONMYA. Broad Medicare, Medicaid and commercial formulary inclusion supports sustained prescription volumes, reduces commercialization friction and improves long‑term revenue visibility if utilization holds.
Improving Revenue And Gross MarginMeaningful year‑over‑year revenue growth with a rapid expansion in gross margin signals improving unit economics and scalability of core products. If this trend persists as sales scale, the company can reduce reliance on external financing and move closer to sustained profitability through operating leverage.
Low Financial LeverageVery low debt reduces solvency and covenant risk, giving management flexibility to prioritize R&D and commercial investments without immediate heavy interest burdens. In a cash‑consuming biotech, minimal leverage preserves optionality for strategic financings or partnerships over the medium term.
Bears Say
High Cash BurnSustained, large negative operating and free cash flows create ongoing funding needs and compress runway absent sizable revenue growth or external financing. Persistent burn elevates dilution risk, forces capital markets dependence, and can constrain long‑term program funding and commercialization cadence.
Deep Net Losses / Weak ReturnsExtremely negative margins and returns show current operations consume far more resources than they generate, implying that scale or structural cost improvement is required. Without successful commercialization or licensing, poor profitability metrics will continue to pressure equity and limit reinvestment capacity.
Key Medical Leadership DepartureThe planned retirement of the Chief Medical Officer creates execution and oversight risk for clinical programs, regulatory interactions and trial continuity. Replacing senior medical leadership can take months, potentially disrupting timelines and increasing uncertainty around pivotal development milestones.
Tonix Pharma News
TNXP FAQ
What was Tonix Pharmaceuticals’s price range in the past 12 months?
Tonix Pharmaceuticals lowest stock price was $10.03 and its highest was $69.97 in the past 12 months.
What is Tonix Pharmaceuticals’s market cap?
Tonix Pharmaceuticals’s market cap is $175.03M.
When is Tonix Pharmaceuticals’s upcoming earnings report date?
Tonix Pharmaceuticals’s upcoming earnings report date is Aug 10, 2026 which is in 19 days.
How were Tonix Pharmaceuticals’s earnings last quarter?
Tonix Pharmaceuticals released its earnings results on May 11, 2026. The company reported -$2.93 earnings per share for the quarter, missing the consensus estimate of -$2.57 by -$0.36.
Is Tonix Pharmaceuticals overvalued?
According to Wall Street analysts Tonix Pharmaceuticals’s price is currently Undervalued.
Does Tonix Pharmaceuticals pay dividends?
Tonix Pharmaceuticals does not currently pay dividends.
What is Tonix Pharmaceuticals’s EPS estimate?
Tonix Pharmaceuticals’s EPS estimate is -2.64.
How many shares outstanding does Tonix Pharmaceuticals have?
Tonix Pharmaceuticals has 15,940,801 shares outstanding.
What happened to Tonix Pharmaceuticals’s price movement after its last earnings report?
Tonix Pharmaceuticals reported an EPS of -$2.93 in its last earnings report, missing expectations of -$2.57. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of Tonix Pharmaceuticals?
Currently, no hedge funds are holding shares in TNXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tonix Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.67 (149.78% Upside)
$37.67 (149.78% Upside)
Blogger Sentiment
Bullish
TNXP Sentiment 70%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth $132.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.59%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
33.72%
Trailing 12-Months
Company Description
Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
TNXP Stock 12 Month Forecast
Average Price Target
$37.67
▲(149.78% Upside)
Technical Analysis
Ownership Overview
0.24% Insiders
6.48% Mutual Funds
<0.01% Other Institutional Investors
83.74% Public Companies and
Individual Investors